Press
releases

Exscalate4CoV supercomputing platform wins 3 million euro EU funding to hunt for new drugs against Coronavirus pandemic

March 6, 2020

Il consorzio Exscalate4CoV progetto di riferimento in Europa per contrastare il Coronavirus con il Supercalcolo

March 6, 2020

Exscalate4CoV: EU’s supercomputing and life science champions gear-up to fight Coronavirus pandemic

February 17, 2020

The Galien Foundation Debuts 2019 Prix Galien USA Nominees in "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Medical Technology" Categories

July 15, 2019

EXSCALATE, EPIDEMICS: Exscalate is the world's most powerful supercomputing platform

April 9, 2019

Dompé receives Industry Innovation Award from the National Organization for Rare Disorders for the Development of Oxervate™ eye drops (cenegermin-bkbj), for neurotrophic keratitis

March 12, 2019

Italian researchers abroad and a startup from Rome win the first Call for Ideas by Dompé. The selected projects concern ophthalmology and the wellness area.

February 20, 2019

Dompé receives FDA approval cenegermin eye drops, first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis

August 22, 2018

Dompé: completed investments cycle for expansion of the production, research and development site in L’Aquila

June 21, 2018

Project NeOn is underway. In Lombardy, the public and private sector have come together to meet the needs of those suffering from diseases of the nervous system and tumours with a high need for treatment.

June 5, 2018

Dompé Farmaceutici S.p.A. Single shareholder company / Share capital € 50.000.000,00
REA MI 289519 - A registered company in Milan, Italy / Tax code and VAT number IT00791570153